EX-99.2 3 catx-ex99_2.htm EX-99.2

Slide 1

Corporate Presentation

Slide 2

 

Slide 3

Developing the Next Generation of Targeted Therapies

Slide 4

Higher Potency Payloads with Cancer-Specific Targeting

Slide 5

 

Slide 6

Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT

Slide 7

 

Slide 8

Perspective’s Innovative Platform

Slide 9

Perspective’s Radiopharmaceutical Platform Optimized for a Broader Therapeutic Window

Slide 10

Perspective’s Proprietary Chelator Has Been Optimized for Lead-Based RPTs

Slide 11

 

Slide 12

 

Slide 13

Proposed Mechanism of Action for 212Pb

Slide 14

Rationale for Synergy with Immune Checkpoint Inhibitors

Slide 15

 

Slide 16

Supply Chain and Manufacturing Infrastructure

Slide 17

On-Demand Order Fulfillment at Regional Sites to Deliver Finished Products

Slide 18

 

Slide 19

Neuroendocrine Tumors: VMT-⍺-NET

Slide 20

 

Slide 21

 

Slide 22

 

Slide 23

Trial Design: [212Pb]VMT-⍺-NET Phase 1/2a For Neuroendocrine Tumors

Slide 24

Anti-Tumor Activity

Slide 25

Signal of Sustained Anti-Tumor Activity

Slide 26

[212Pb]VMT-α-NET Was Well Tolerated

Slide 27

No Decline in Renal Function Observed

Slide 28

 

Slide 29

Patient with PR after [212Pb]VMT-α-NET

Slide 30

Melanoma Program: VMT01/02

Slide 31

 

Slide 32

 

Slide 33

 

Slide 34

 

Slide 35

Trial Design: [212Pb]VMT01 Phase 1/2a For Metastatic Melanoma

Slide 36

 

Slide 37

Treatment Emergent Adverse Events (occurring in ≥ 2 patients and/or Grade ≥ 2)

Slide 38

 

Slide 39

 

Slide 40

 

Slide 41

 

Slide 42

 

Slide 43

PSV359 is Active Against FAP-α Expression on Tumor and on Stroma

Slide 44

 

Slide 45

 

Slide 46

Trial Design: [212Pb]PSV359 Phase 1/2a Trial

Slide 47

 

Slide 48

General Corporate Information

Slide 49

 

Slide 50

 

Slide 51

 

Slide 52

 

Slide 53

Abbreviations

Slide 54

APPENDIX

Slide 55

 

Slide 56

NETs Trials

Slide 57

Refractory Metastatic Melanoma Trials

Slide 58

 

Slide 59

 

Slide 60

 

Slide 61

 

Slide 62

 

Slide 63

Perspective’s Pre-Targeting Platform